Regulation of B Lymphocyte Survival and Differentiation by HSH2

HSH2 对 B 淋巴细胞存活和分化的调节

基本信息

  • 批准号:
    7775050
  • 负责人:
  • 金额:
    $ 31.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-03-05 至 2012-02-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The goal of this application is to elucidate the physiological role of the novel adaptor protein HSH2 (Hematopoietic SH2 protein) in regulation of B lymphocyte biology. Studies conducted in our laboratory have demonstrated that HSH2 is expressed at low basal levels in splenic B cells and that its expression is induced in response to stimuli that bind to distinct families of receptors that promote survival and differentiation, including CD40L, IL-4, LPS, CpG DMA and BLyS (BAFF). Up-regulation of HSH2 expression was shown to be dependent on activation of NF-?B and correlates with initiation of a survival response that includes up-.regulation of Bcl-XL. Retroviral-mediated expression of HSH2 in the WEHI-231 B cell line, which undergoes apoptosis in response to BCR ligation, was observed to enhance survival and mitochondrial stability. Similarly, enhanced survival of WEHI-231 cells in response to CD40-mediated signaling directly correlated with up-regulation of HSH2 expression. Although HSH2 does not significantly alter BCR-proximal signal transduction, it was observed to maintain mitochondrial stability and this correlated with its ability to block up-regulation of Bim in response to BCR signaling. Moreover, HSH2 was found to interact with the anti-apoptotic protein HAX-1, which possesses a membrane-spanning region that targets it to the outer mitochondrial membrane. Preliminary studies have shown that the interaction between HSH2 and HAX-1 is important for the anti-apoptotic activity of HSH2. Therefore, HSH2 and HAX-1 may function together to regulate mitochondrial integrity and cell survival. To further elucidate the physiological role of HSH2 in regulation of B lymphocyte survival/differentiation, three specific aims have been proposed that will: 1) determine the physiological role of HSH2 in B lymphocyte development, homeostasis and immune function; 2) elucidate the role that HSH2 plays in regulating Bim expression in response to co-stimulation; and 3) determine the functional importance of the interaction between HSH2 and HAX-1 in regulating mitochondrial stability. Because HSH2 expression is induced in response to many of the key stimuli that are known to promote B cell survival and differentiation, this adaptor protein is likely to play an important role in regulating B cell homeostasis and immune function. Therefore, these studies will provide novel insight into the molecular mechanisms that maintain the balance between B lymphocyte survival and death leading to differentiation into humoral effector cells and will provide insight into the etiology and progression of diseases associated with aberrant B cell function, including cancer and autoimmunity.
描述(由申请人提供):本申请的目的是阐明新型衔接蛋白HSH 2(造血SH 2蛋白)在B淋巴细胞生物学调节中的生理作用。在我们实验室进行的研究已经证明,HSH 2在脾B细胞中以低基础水平表达,并且其表达响应于结合促进存活和分化的不同受体家族的刺激而被诱导,所述受体家族包括CD 40 L、IL-4、LPS、CpG DMA和BLyS(BAFF)。HSH 2表达的上调被证明是依赖于NF-?B,并与包括上调Bcl-XL的存活应答的起始相关。在WEHI-231 B细胞系中,观察到逆转录病毒介导的HSH 2表达增强了存活和线粒体稳定性,WEHI-231细胞系响应于BCR连接而经历凋亡。类似地,响应于CD 40介导的信号传导的WEHI-231细胞的增强的存活与HSH 2表达的上调直接相关。尽管HSH 2不显著改变BCR近端信号转导,但观察到其维持线粒体稳定性,这与其阻断Bim响应BCR信号转导的上调的能力相关。此外,发现HSH 2与抗凋亡蛋白HAX-1相互作用,HAX-1具有将其靶向线粒体外膜的跨膜区域。初步研究表明,HSH 2和HAX-1之间的相互作用对于HSH 2的抗凋亡活性是重要的。因此,HSH 2和HAX-1可能共同作用以调节线粒体完整性和细胞存活。为了进一步阐明HSH 2在调节B淋巴细胞存活/分化中的生理作用,提出了三个具体目标:1)确定HSH 2在B淋巴细胞发育、稳态和免疫功能中的生理作用; 2)阐明HSH 2在响应共刺激调节Bim表达中的作用;以及3)确定HSH 2和HAX-1之间的相互作用在调节线粒体稳定性中的功能重要性。因为HSH 2表达是响应于已知促进B细胞存活和分化的许多关键刺激而诱导的,所以这种衔接蛋白可能在调节B细胞稳态和免疫功能中起重要作用。因此,这些研究将为维持B淋巴细胞存活和死亡之间的平衡,导致分化为体液效应细胞的分子机制提供新的见解,并将为与异常B细胞功能相关的疾病(包括癌症和自身免疫)的病因学和进展提供见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LOUIS B JUSTEMENT其他文献

LOUIS B JUSTEMENT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LOUIS B JUSTEMENT', 18)}}的其他基金

Identification and Analysis of the Physiological Ligand for TLT2
TLT2生理配体的鉴定与分析
  • 批准号:
    8568235
  • 财政年份:
    2013
  • 资助金额:
    $ 31.69万
  • 项目类别:
CD19 Tyrosine-mediated Signal Transduction in vivo
CD19 酪氨酸介导的体内信号转导
  • 批准号:
    8081969
  • 财政年份:
    2010
  • 资助金额:
    $ 31.69万
  • 项目类别:
Regulation of B Lymphocyte Survival and Differentiation by HSH2
HSH2 对 B 淋巴细胞存活和分化的调节
  • 批准号:
    7612425
  • 财政年份:
    2008
  • 资助金额:
    $ 31.69万
  • 项目类别:
Regulation of B Lymphocyte Survival and Differentiation by HSH2
HSH2 对 B 淋巴细胞存活和分化的调节
  • 批准号:
    7367189
  • 财政年份:
    2007
  • 资助金额:
    $ 31.69万
  • 项目类别:
Regulation of B Lymphocyte Survival and Differentiation by HSH2
HSH2 对 B 淋巴细胞存活和分化的调节
  • 批准号:
    7191849
  • 财政年份:
    2007
  • 资助金额:
    $ 31.69万
  • 项目类别:
Regulation of B Lymphocyte Survival and Differentiation by HSH2
HSH2 对 B 淋巴细胞存活和分化的调节
  • 批准号:
    8030421
  • 财政年份:
    2007
  • 资助金额:
    $ 31.69万
  • 项目类别:
Regulation of B Lymphocyte Survival and Differentiation by HSH2
HSH2 对 B 淋巴细胞存活和分化的调节
  • 批准号:
    7586201
  • 财政年份:
    2007
  • 资助金额:
    $ 31.69万
  • 项目类别:
CD19 Tyrosine-mediated Signal Transduction in vivo
CD19 酪氨酸介导的体内信号转导
  • 批准号:
    7647892
  • 财政年份:
    1998
  • 资助金额:
    $ 31.69万
  • 项目类别:
CD19 Tyrosine-mediated Signal Transduction in vivo
CD19 酪氨酸介导的体内信号转导
  • 批准号:
    7533208
  • 财政年份:
    1998
  • 资助金额:
    $ 31.69万
  • 项目类别:
CD19 Tyrosine-mediated Signal Transduction in vivo
CD19 酪氨酸介导的体内信号转导
  • 批准号:
    8289609
  • 财政年份:
    1998
  • 资助金额:
    $ 31.69万
  • 项目类别:

相似海外基金

Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
  • 批准号:
    23K06728
  • 财政年份:
    2023
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
  • 批准号:
    MR/W031353/1
  • 财政年份:
    2022
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Research Grant
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
  • 批准号:
    2145853
  • 财政年份:
    2022
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
  • 批准号:
    22K06603
  • 财政年份:
    2022
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10701754
  • 财政年份:
    2022
  • 资助金额:
    $ 31.69万
  • 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10557760
  • 财政年份:
    2022
  • 资助金额:
    $ 31.69万
  • 项目类别:
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
  • 批准号:
    20H03536
  • 财政年份:
    2020
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
  • 批准号:
    437200
  • 财政年份:
    2020
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Studentship Programs
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    10542442
  • 财政年份:
    2020
  • 资助金额:
    $ 31.69万
  • 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    10321545
  • 财政年份:
    2020
  • 资助金额:
    $ 31.69万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了